Haleon (HLN) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Haleon (NYSE:HLN) is set to announce its quarterly earnings on Thursday, August 7th, with analysts expecting earnings of $0.24 per share and revenue of $7.48 billion.
• The company has received mixed ratings from analysts, with a recent upgrade to a "strong-buy" by BNP Paribas and an average price target of $12.33.
• Several large investors, such as Geneos Wealth Management Inc. and AQR Capital Management LLC, have increased their stakes in Haleon, indicating growing institutional interest.

Haleon (NYSE:HLN - Get Free Report) is expected to be announcing its H1 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $0.24 per share and revenue of $7.48 billion for the quarter.

Haleon Stock Performance

HLN traded up $0.24 during trading hours on Friday, hitting $9.67. The company's stock had a trading volume of 16,930,452 shares, compared to its average volume of 11,525,428. Haleon has a fifty-two week low of $8.86 and a fifty-two week high of $11.42. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. The firm has a market capitalization of $43.44 billion, a PE ratio of 24.80, a PEG ratio of 2.73 and a beta of 0.23. The company has a 50-day simple moving average of $10.37 and a 200 day simple moving average of $10.18.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HLN shares. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. BNP Paribas upgraded Haleon to a "strong-buy" rating in a research report on Tuesday, May 27th. Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price target on the stock in a research report on Tuesday, May 27th. Finally, Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. Six research analysts have rated the stock with a hold rating, four have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Haleon has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Hedge Funds Weigh In On Haleon

Several hedge funds have recently modified their holdings of HLN. Brighton Jones LLC bought a new stake in shares of Haleon during the 4th quarter worth $187,000. AQR Capital Management LLC boosted its stake in shares of Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company's stock worth $991,000 after acquiring an additional 17,720 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Haleon by 7.6% during the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company's stock worth $752,000 after acquiring an additional 5,178 shares in the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company's stock worth $50,000 after acquiring an additional 1,203 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.